Nabriva Therapeutics plc (NBRV)の価格はいくらですか

Nabriva Therapeutics plc (NBRV)の価格は$0.63です

Nabriva Therapeutics plc (NBRV)の時価総額は何ですか

Nabriva Therapeutics plc (NBRV)の時価総額は$284.20Kです

Nabriva Therapeutics plc（NBRV）株式分割

Nabriva Therapeutics plc is a biopharmaceutical company focused on the discovery and commercialization of innovative anti-infective medications to combat serious infections. The company's current marketed products include SIVEXTRO, an oxazolidinone-class antibacterial designed for the treatment of acute bacterial skin and skin structure infections (ABSSSI), and XENLETA, a semi-synthetic pleuromutilin antibiotic utilized in managing community-acquired bacterial pneumonia. Beyond its existing offerings, Nabriva is further exploring XENLETA's potential in Phase I clinical trials for a broad spectrum of indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated and hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Additionally, the firm is developing CONTEPO, an epoxide antibiotic for complicated urinary tract infections, which is also undergoing Phase I clinical evaluation for peri-operative prophylaxis. Originally incorporated in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and maintains its corporate headquarters in Dublin, Ireland.

年	株式分割	分割比率	累積分割比率
提供された日付のデータは十分ではありません。

年

株式分割

分割比率

累積分割比率

提供された日付のデータは十分ではありません。

企業	株式分割の回数	累積分割比率	国
Vertex Pharmaceuticals Incorporated VRTX.US	1	x2	US
Argenx SE ARGX.US	0	-	NL
Lonza Group AG LONN.SW	0	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	0	-	KR
UCB S.A. UCB.BR	0	-	BE

企業

株式分割の回数

累積分割比率

国